Sarah Zohar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6428993/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1298.	7.4	388
2	Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurology, The, 2015, 14, 469-477.	10.2	208
3	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. Neuro-Oncology, 2006, 8, 60-66.	1.2	189
4	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncology, 2010, 12, 401-408.	1.2	180
5	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Annals of the Rheumatic Diseases, 2008, 67, 98-104.	0.9	149
6	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase l–II study. British Journal of Haematology, 2002, 119, 726-739.	2.5	119
7	Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 121-132.	1.5	112
8	The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Statistics in Medicine, 2001, 20, 2827-2843.	1.6	100
9	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer, 2017, 70, 133-142.	2.8	86
10	Late Morbidity After Colon Interposition for Corrosive Esophageal Injury. Annals of Surgery, 2010, 252, 271-280.	4.2	80
11	Surgery for Caustic Injuries of the Upper Gastrointestinal Tract. Annals of Surgery, 2012, 256, 994-1001.	4.2	64
12	Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer, 2006, 94, 609-613.	6.4	63
13	A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. British Journal of Cancer, 2006, 95, 253-259.	6.4	55
14	Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Annals of Oncology, 2015, 26, 669-674.	1.2	53
15	Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research, 2019, 85, 943-954.	2.3	52
16	A Bayesian doseâ€finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics, 2014, 13, 247-257.	1.3	50
17	Doseâ€finding designs using a novel quasiâ€continuous endpoint for multiple toxicities. Statistics in Medicine, 2013, 32, 2728-2746.	1.6	45
18	Doseâ€finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal, 2017, 59, 804-825.	1.0	41

#	Article	lF	CITATIONS
19	Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 1071-1083.	0.8	40
20	Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial. Contemporary Clinical Trials, 2008, 29, 608-616.	1.8	40
21	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.8	40
22	Esophageal replacement by allogenic aorta in a porcine model. Surgery, 2010, 148, 39-47.	1.9	39
23	Doseâ€finding approach for dose escalation with overdose control considering incomplete observations. Statistics in Medicine, 2011, 30, 1584-1594.	1.6	39
24	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. Journal of Rheumatology, 2009, 36, 1460-1463.	2.0	38
25	Anal Carcinoma in HIV-Infected Patients in the Era of Antiretroviral Therapy: A Comparative Study. Diseases of the Colon and Rectum, 2011, 54, 729-735.	1.3	38
26	Competing designs for drug combination in phase I doseâ€finding clinical trials. Statistics in Medicine, 2015, 34, 1-12.	1.6	36
27	Colopharyngoplasty for the Treatment of Severe Pharyngoesophageal Caustic Injuries. Annals of Surgery, 2007, 246, 721-727.	4.2	35
28	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine, 2003, 72, 117-125.	4.7	34
29	Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion, 2007, 47, 1851-1857.	1.6	31
30	Incorporating lower grade toxicity information into dose finding designs. Clinical Trials, 2011, 8, 370-379.	1.6	31
31	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 2017, 12, 44.	2.7	31
32	Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research, 2018, 27, 466-479.	1.5	31
33	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research, 2020, 12, 461-477.	0.8	31
34	A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent with a Molecularly Targeted Agent. Journal of the Royal Statistical Society Series C: Applied Statistics, 2015, 64, 215-229.	1.0	30
35	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases, 2018, 13, 186.	2.7	30
36	Optimal designs for estimating the most successful dose. Statistics in Medicine, 2006, 25, 4311-4320.	1.6	29

#	Article	IF	CITATIONS
37	Retrospective Robustness of the Continual Reassessment Method. Journal of Biopharmaceutical Statistics, 2010, 20, 1013-1025.	0.8	27
38	Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal, 2017, 59, 609-625.	1.0	27
39	Identifying the most successful dose (MSD) in dose-finding studies in cancer. Pharmaceutical Statistics, 2006, 5, 187-199.	1.3	26
40	An adaptive power prior for sequential clinical trials – Application to bridging studies. Statistical Methods in Medical Research, 2020, 29, 2282-2294.	1.5	25
41	Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. Journal of the American Statistical Association, 2014, 109, 931-943.	3.1	24
42	Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 479-485.	1.5	23
43	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clinical Trials, 2008, 5, 478-485.	1.6	23
44	Application of the Continual Reassessment Method to Dose-finding Studies in Regional Anesthesia. Anesthesiology, 2013, 119, 29-35.	2.5	22
45	The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplantation, 2006, 37, 725-729.	2.4	21
46	Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials, 2013, 10, 414-421.	1.6	21
47	Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Clinical Trials, 2008, 5, 595-606.	1.6	20
48	Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research, 2016, 25, 1022-1038.	1.5	20
49	The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials. Clinical Cancer Research, 2012, 18, 5179-5187.	7.0	19
50	Primary Hyperparathyroidism from Parathyroid Microadenoma: Specific Features and Implications for a Surgical Strategy in the Era of Minimally Invasive Parathyroidectomy. Journal of the American College of Surgeons, 2010, 210, 456-462.	0.5	18
51	Bumetanide for neonatal seizures—back from the cotside. Nature Reviews Neurology, 2015, 11, 724-724.	10.1	18
52	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. Statistical Methods in Medical Research, 2018, 27, 1860-1877.	1.5	17
53	Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Statistics in Medicine, 2011, 30, 1563-1573.	1.6	16
54	Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17, 214-230.	1.3	16

#	Article	IF	CITATIONS
55	Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. BMJ Open, 2019, 9, e022739.	1.9	15
56	Planning a Bayesian earlyâ€phase phase I/II study for human vaccines in HER2 carcinomas. Pharmaceutical Statistics, 2011, 10, 218-226.	1.3	14
57	Similar Outcomes After Primary and Secondary Esophagocoloplasty for Caustic Injuries. Annals of Thoracic Surgery, 2012, 93, 905-912.	1.3	14
58	A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology. Clinical Pharmacokinetics, 2009, 48, 387-395.	3.5	13
59	Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. Bone Marrow Transplantation, 2009, 43, 919-925.	2.4	12
60	Sensitivity of dose-finding studies to observation errors. Contemporary Clinical Trials, 2009, 30, 523-530.	1.8	12
61	An approach to metaâ€analysis of doseâ€finding studies. Statistics in Medicine, 2011, 30, 2109-2116.	1.6	12
62	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. BMC Medical Research Methodology, 2018, 18, 20.	3.1	12
63	Dose-finding designs for cumulative toxicities using multiple constraints. Biostatistics, 2019, 20, 17-29.	1.5	12
64	Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design. Journal of Biopharmaceutical Statistics, 2003, 13, 87-101.	0.8	11
65	Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. Biometrics, 2022, 78, 300-312.	1.4	11
66	A Bayesian predictive sample size selection design for singleâ€∎rm exploratory clinical trials. Statistics in Medicine, 2012, 31, 4243-4254.	1.6	10
67	A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica, 2006, 91, 550-3.	3.5	10
68	Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clinical Trials, 2013, 10, 505-514.	1.6	9
69	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. PLoS ONE, 2016, 11, e0166207.	2.5	9
70	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases, 2016, 11, 16.	2.7	9
71	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Statistical Methods in Medical Research, 2020, 29, 541-567.	1.5	8
72	Re: Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 2009, 101, 1732-1733.	6.3	7

#	Article	IF	CITATIONS
73	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. Antimicrobial Agents and Chemotherapy, 2016, 60, 1481-1491.	3.2	7
74	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 2018, 157, 163-177.	4.7	7
75	Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical Methods in Medical Research, 2019, 28, 404-418.	1.5	7
76	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research, 2020, 12, 478-482.	0.8	7
77	An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. Statistics in Medicine, 2015, 34, 3029-3039.	1.6	6
78	Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. Statistics in Medicine, 2021, 40, 5096-5114.	1.6	6
79	What is the ED 95 of prilocaine for femoral nerve block using ultrasound? â€. British Journal of Anaesthesia, 2013, 110, 831-836.	3.4	5
80	Bayesian variable selection based on clinical relevance weights in small sample studies—Application to colon cancer. Statistics in Medicine, 2019, 38, 2228-2247.	1.6	5
81	Alternate designs for conduct and analysis of phase I cancer trials. Blood, 2001, 98, 1275-1275.	1.4	4
82	A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. Methods of Information in Medicine, 2016, 55, 4-13.	1.2	4
83	A Bayesian non-inferiority approach using experts' margin elicitation – application to the monitoring of safety events. BMC Medical Research Methodology, 2019, 19, 187.	3.1	4
84	Bayesian sample size determination for phase IIA clinical trials using historical data and semiâ€parametric prior's elicitation. Pharmaceutical Statistics, 2019, 18, 198-211.	1.3	4
85	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. PLoS ONE, 2016, 11, e0156096.	2.5	4
86	Estimating Similarity of Dose–Response Relationships in Phase I Clinical Trials—Case Study in Bridging Data Package. International Journal of Environmental Research and Public Health, 2021, 18, 1639.	2.6	3
87	Random-effects meta-analysis of Phase I dose-finding studies using stochastic process priors. Annals of Applied Statistics, 2021, 15, .	1.1	3
88	The Continual Reassessment Method. , 2006, , 131-148.		2
89	dfcomb: An R-package for phase I/II trials of drug combinations. Computer Methods and Programs in Biomedicine, 2016, 125, 117-133.	4.7	2
90	A Dose Finding Design for Seizure Reduction in Neonates. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 427-444.	1.0	2

#	Article	IF	CITATIONS
91	Maximum-relevance weighted likelihood estimator: application to the continual reassessment method. Statistics and Its Interface, 2010, 3, 177-183.	0.3	2
92	Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. Melanoma Research, 2009, 19, 379-384.	1.2	1
93	Response to comments on †Competing designs for drug combination in phase I doseâ€finding clinical trials' by G. Yin, R. Lin and N. Wages. Statistics in Medicine, 2015, 34, 23-26.	1.6	1
94	Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. Archives of Disease in Childhood, 2018, 103, archdischild-2018-314874.	1.9	1
95	The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. Pharmaceutics, 2021, 13, 601.	4.5	1
96	Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. Bayesian Analysis, 2021, 16, .	3.0	1
97	A straightforward metaâ€analysis approach for oncology phase I doseâ€finding studies. Statistics in Medicine, 2022, 41, 3915-3940.	1.6	1
98	Defining Stopping Rules. , 2006, , 205-224.		0
99	Websites and Software. , 2006, , 287-306.		Ο
100	Dose Estimation. Pharmaceutical Medicine, 2008, 22, 35-40.	1.9	0
101	An adaptive model switching approach for phase I doseâ€finding trials. Pharmaceutical Statistics, 2013, 12, 225-232.	1.3	Ο
102	Comments on †A comparative study of adaptive doseâ€finding designs for phase I oncology trials of combination therapies'. Statistics in Medicine, 2016, 35, 475-478.	1.6	0
103	Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies. Statistics in Biosciences, 2021, 13, 142-159.	1.2	О